Balaji Desai, MD
Internal Medicine · Danville, VANPI 1932385028
Payments from drug & device makers
Across 162 payments — averaging $16.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$731
- Novo Nordisk$330
- Novartis$157
- Merck$150
- Johnson & Johnson$126
- Pfizer$125
- plus $1K from 32 others
What the payments were for
- Food & beverage$2,638100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 45 | $731 |
| Novo Nordisk | 21 | $330 |
| Novartis | 9 | $157 |
| Merck | 9 | $150 |
| Johnson & Johnson | 13 | $126 |
| Pfizer | 9 | $125 |
| Amgen(2 entities) | 6 | $88 |
| Corcept Therapeutics | 4 | $79 |
| Boehringer Ingelheim | 4 | $78 |
| E.r. Squibb & Sons, L.L.C. | 1 | $69 |
| Lilly USA, LLC | 4 | $68 |
| Esperion Therapeutics, Inc. | 4 | $57 |
| Aimmune Therapeutics, Inc. | 2 | $55 |
| Inspire Medical Systems, Inc. | 1 | $54 |
| Viiv Healthcare Company | 3 | $48 |
| Amarin Pharma, Inc. | 3 | $43 |
| AstraZeneca | 3 | $38 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Paratek Pharmaceuticals, Inc. | 1 | $24 |
| Vyera Pharmaceuticals, LLC | 1 | $23 |
| Insulet Corporation | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Corium, LLC | 1 | $19 |
| Philips North America LLC | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Alkermes, Inc. | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Biogen | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Bayer | 1 | $15 |
| Melinta Therapeutics, LLC | 1 | $15 |
| Astellas Pharma US Inc | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Strongbridge US Inc. | 1 | $11 |
| Sunovion Pharmaceuticals Inc. | 1 | $11 |
How this compares
$2,644 in reported general payments places this provider in the 85th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 53 | $231,004 |
| OzempicSemaglutide | 132 | $163,222 |
| TivicayDolutegravir Sodium | 44 | $107,437 |
| Daptomycin | 27 | $72,870 |
| DescovyEmtricitabine/Tenofov Alafenam | 30 | $70,764 |
| TrulicityDulaglutide | 37 | $61,198 |
| TradjentaLinagliptin | 70 | $57,157 |
| PrezcobixDarunavir/Cobicistat | 21 | $51,294 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 11 | $47,907 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 13 | $47,743 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 11 | $43,650 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 12 | $43,478 |
| LinzessLinaclotide | 52 | $40,025 |
| EliquisApixaban | 58 | $37,154 |
| JanuviaSitagliptin Phosphate | 60 | $37,091 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyTivicay, Triumeq, Dovato | $48 | $187,39768 claims |
| Novo NordiskOzempic | $330 | $163,222132 claims |
| Johnson & JohnsonPrezcobix, Xarelto | $126 | $86,02056 claims |
| Boehringer IngelheimTradjenta, Jardiance | $78 | $81,44996 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $68 | $78,21354 claims |
| AbbVieLinzess, Synthroid | $731 | $43,39999 claims |
| PfizerEliquis | $125 | $37,15458 claims |
| MerckJanuvia | $150 | $37,09160 claims |
| AstraZenecaFarxiga | $38 | $18,09524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Danville
- Daniel PomposiniDanville$213K
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
- Richard JacksonRichmond$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.